Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/annual-reviews/neuroprotection-in-glaucoma-animal-models-and-clinical-trials-6TzupVJc0H
- Publisher
- Annual Reviews
- Copyright
- Copyright 2017 by Annual Reviews. All rights reserved
- ISSN
- 2374-4642
- eISSN
- 2374-4650
- DOI
- 10.1146/annurev-vision-102016-061422
- pmid
- 28731838
- Publisher site
- See Article on Publisher Site
Abstract
Glaucoma is a progressive neurodegenerative disease that frequently results in irreversible blindness. Glaucoma causes death of retinal ganglion cells (RGCs) and their axons in the optic nerve, resulting in visual field deficits and eventual loss of visual acuity. Glaucoma is a complex optic neuropathy, and a successful strategy for its treatment requires not only better management of known risk factors such as elevated intraocular pressure and the development of improved tools for detecting RGC injury but also treatments that address this injury (i.e., neuroprotection). Experimental models of glaucoma provide insight into the cellular and molecular mechanisms of glaucomatous optic neuropathy and aid the development of neuroprotective therapies.
Journal
Annual review of vision science – Annual Reviews
Published: Sep 15, 2017